ArticleFrontiers in cardiovascular medicine2025
OCT-based vulnerable plaque features and MACE prediction in premature coronary artery disease.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Optical coherence tomography-derived macrophage arc as a novel biomarker for predicting adverse cardiovascular events in coronary artery disease: a multicentre study.European heart journal. Imaging methods and practice · 2026Article
- Cellular and Molecular Mechanisms of Hyperglycemia-Induced Atherosclerosis and Intervention Strategies of Chinese Herbal Medicine.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to systematically analyze coronary plaque characteristics in patients with premature coronary artery disease (PCAD) using optical coherence tomography (OCT) and clarify their associations with clinical risk factors and major adverse cardiovascular events (MACE). Methods: A total of 224 patients (men ≤55 years, women ≤65 years) with suspected or confirmed CAD who underwent coronary angiography and OCT at the First Affiliated Hospital of Nanjing Medical University between February 2022 and February 2024 were enrolled. Among them, 142 were diagnosed with PCAD (observation group), and 82 had coronary stenosis <50% (control group). Baseline clinical data, risk factors, and OCT-derived plaque features were collected. Patients were followed for 12 months to record MACE. Statistical analyses included independent Results: The PCAD group exhibited significantly higher prevalence rates of hypertension (63.38% vs. 47.56%), smoking (30.28% vs. 17.07%), and diabetes (19.72% vs. 8.54%), along with elevated total cholesterol (4.89 ± 1.41 vs. 4.41 ± 1.32 mmol/L), LDL-C (2.91 ± 0.98 vs. 2.51 ± 0.72 mmol/L), and lipoprotein(a) (50.2 ± 28.4 vs. 30.5 ± 18.7 mg/dl) compared to controls (all Conclusion: Patients with PCAD demonstrate distinct coronary plaque vulnerability features closely associated with metabolic and lifestyle-related risk factors. OCT enables precise identification of high-risk plaques, providing critical insights for early intervention and risk stratification to mitigate acute cardiovascular events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.